Dr. John D. Rather
President and CEO of SEI, Dr. John D.G. Rather, has a proven history of mobilizing scientists and engineers — leaders in physical and biogenetic sciences — to achieve high-leverage, strategic advantages for industry and government.
Dr. Rather is known internationally as a scientific innovator and creator of major technology programs. His experience in business and government spans defense, space, medical, and industrial communities. Dr. Rather worked in physics and space research at three National Laboratories before moving into the business sector to create and manage large applied research and development initiatives. This work led to high-level involvement with the U.S. Government, where he frequently provided invited expert testimony to the U.S. House, Senate, and White House concerning issues of technology and science policy.
During the 1980s, Dr. Rather became Vice President for Research and Technology Innovation at Kaman Aerospace Corporation, where he led that Fortune 500 company into profitable new directions. In 1990, he was recruited to join the Senior Executive Service of the U.S. Government at NASA. As Manager, Advanced Concepts Systems Integration, he mobilized innovators in NASA, other government agencies and U.S. industries to accelerate space systems development. In 1992, he served as Chairman of the NASA/DOE study of asteroid impact prevention mandated by the U.S. House of Representatives. For more than twenty years he was also a contributor at the D.I.A. and the C.I.A. In 1997, the Barbara Ann Karmanos Cancer Institute, then affiliated with Wayne State University (WSU) in Detroit, created a new position for Dr. Rather. His new concepts, utilizing physics and engineering applied to cancer detection and cure, generated large financial support for Karmanos R&D. He was also named University Professor of Physics at WSU. Dr. Rather founded the Rather Creative Innovations Group, Inc. (RCIG, Inc.) in 2006 to create new opportunities for economic and societal growth and to engender focused revolutionary technology breakthroughs. The RCIG website is http://www.RCIGinc.com.
Dr. Dean S. Hartley III
Vice President and COO of SEI, Dr. Dean S. Hartley III, has a proven history of completing projects — involving multiple disciplines — to achieve high-leverage, strategic advantages for industry and government.
Dr. Hartley is known internationally as a problem solver and expert in operations research (OR). Operations Research is the "Science of Better," the discipline of modeling complex problems to make better decisions. He has been solving problems for customers for more than forty years: two years while in graduate school, four years while on active duty in the Army, nine years in private industry at Milliken, fifteen years at the Oak Ridge Federal Facilities, and fourteen years as Principal of Hartley Consulting. The Hartley Consulting website is http://DrDeanHartley.com.
Hartley is a past Vice President of the Institute for Operations Research and Management Science (INFORMS), a past Director of the Military Operations Research Society (MORS), past President of the Military Applications Society (MAS), and a member of the INFORMS Simulation Society (ISIM). He also serves as the Technical Advisor for Operations Research and Modeling to the International Psychopharmacology Algorithm Project (IPAP). Hartley is a Senior Fellow with the George Mason University School of Public Policy, a consulting resource for the Naval Postgraduate School (NPS), MOVES Institute, and a Research Fellow with the University of Alabama in Huntsville, CMOST. Hartley has published Predicting Combat Effects, co-authored two books, contributed numerous chapters to other books, and written more than 150 articles and technical documents. In 1994 he was awarded the Koopman Prize for best publication in military operations research and in 2013 he was awarded the Steinhardt Prize for lifetime achievement in operations research. His expertise includes modeling and simulation of combat, irregular warfare (IW) operations, verification, validation, and accreditation (VV&A) of models, and psychopharmacology modeling.